FY2025 EPS Estimates for BioNTech Increased by HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Equities researchers at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for BioNTech in a note issued to investors on Monday, November 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($4.62) per share for the year, up from their previous estimate of ($6.90). HC Wainwright has a “Buy” rating and a $140.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2025 earnings at ($0.62) EPS, Q1 2026 earnings at ($2.26) EPS, Q2 2026 earnings at ($2.28) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at $1.13 EPS and FY2026 earnings at ($6.66) EPS.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS.

Several other analysts have also recently commented on BNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. UBS Group lifted their target price on BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research note on Monday, November 3rd. JPMorgan Chase & Co. cut their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Finally, Cowen reaffirmed a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $134.10.

BioNTech Price Performance

BNTX stock opened at $108.65 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The company’s fifty day moving average price is $102.87 and its 200-day moving average price is $104.91. BioNTech has a one year low of $81.20 and a one year high of $129.27. The company has a market capitalization of $24.47 billion, a PE ratio of -67.91 and a beta of 1.54.

Institutional Trading of BioNTech

A number of institutional investors have recently bought and sold shares of BNTX. Financial Consulate Inc. purchased a new position in BioNTech during the third quarter worth $36,000. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech in the 1st quarter worth about $36,000. LRI Investments LLC lifted its holdings in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 312 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the period. Finally, Hantz Financial Services Inc. grew its holdings in BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.